Educational overview · Approx. 4 min read · illustrative, not advice
Fifteen pages on how this category actually works, what it costs you in effort and exposure, and how to interrogate anyone who offers to build it for you. Including us.
What this document is
This is an operating blueprint, not a pitch deck. It describes how a cash-pay metabolic health business is assembled in 2026: the legal structures available, the clinical staffing question, the technology and supply chains underneath it, how members are acquired and kept, and the specific ways the model can fail.
It is written to be useful if you never speak to us. If you read all fifteen pages and go build this yourself, or hire a lawyer and a fractional operator and assemble it piece by piece, the document has done its job. We would rather be judged on whether the analysis holds up than on whether the brochure was persuasive.
Atlas Metabolic licenses a complete white-label metabolic health build to a partner. That is what we sell, and page fifteen tells you how to start that conversation. Pages two through fourteen are the category, not the company.
- Fifteen discrete pages, each self-contained
- Every statistic carries a named public source
- Claims we reasoned to rather than sourced are labelled INFERENCE
- Nothing here is legal, medical, tax or financial advice
What this document is not
There are no income numbers in this blueprint. Not a revenue projection, not a margin table, not a payback period, not an illustrative example with figures attached. That is deliberate and it is not modesty.
A company selling a business build that shows you earnings figures without a Franchise Disclosure Document is showing you a number nobody audited, nobody substantiated, and nobody is accountable for. Atlas has no FDD. So Atlas shows no earnings figures. If you have been shown such numbers by anyone in this category, page fourteen tells you exactly what to ask for next.
There is also no price in this document. Where a fee would naturally appear you will see The license fee is one-time. It carries 0% of revenue and no ongoing partner fees. The figure is not published anywhere, by design — it is disclosed in full on the fit call, where it can be put next to what it covers instead of floating on its own.. The license fee is disclosed on a fit call, in context, against what is actually being delivered. We explain the reasoning on page fifteen rather than asking you to accept it here.
How the pages are organised
Pages two through four establish whether you are the right reader and whether the market is real. Pages five through nine are structure: franchise versus license, the entity question, clinical staffing, technology, and supply. Pages ten and eleven are the commercial engine, acquisition and retention. Page twelve is the sequence. Pages thirteen and fourteen are the ones that matter most.
If you only have ten minutes, read page thirteen and page fourteen. Page thirteen states the risks in this category without softening them. Page fourteen is a diligence instrument you can point at any company selling you a build, including this one.
On sources
Every figure in this blueprint traces to a named publisher: CDC and the National Center for Health Statistics for prevalence, KFF for adoption and coverage, FDA and the Federal Register for compounding policy, Morgan Stanley, Goldman Sachs and Grand View Research for market forecasts, the AMA for liability costs, the Milbank Memorial Fund for corporate practice of medicine.
Where the widely repeated number in this industry could not be traced to a real source, we say so and omit it. Several commonly cited startup-cost and prescription-volume figures fall into that category. A blueprint that quietly repeats unsourced numbers is worth less than one that admits the gap.
Where to start if you are new to the category
If the vocabulary is unfamiliar, three of our library pieces set the baseline before you continue: what turnkey actually means when a company uses the word, how to start a wellness business as a general matter, and a plain overview of the metabolic wellness market. None of them require you to have read this blueprint first.
Otherwise, turn the page. Page two is about disqualification, and it is honest about it.
- US FDA — FDA does not evaluate specific compounded products for safety, effectiveness, manufacturing quality or consistency, and has received hundreds of adverse event reports associated with compounded semaglutide and tirzepatide. (source) [VERIFIED]
- Atlas Metabolic editorial policy — This blueprint publishes no earnings figures because Atlas has no Franchise Disclosure Document and therefore no substantiated basis for any earnings representation. [INFERENCE]